Infrastructure resources for clinical research in amyotrophic lateral sclerosis

Pubs
Affiliates	Alexander V. Sherman [1], Amelie K. Gubitz [2], Ammar AlChalabi [3], Richard Bedlack [4], James Berry [5], Robin Conwit [2], Brent T. Harris [6], D. Kevin Horton [7], Petra Kaufmann [2], Melanie L. Leitner [8], Robert Miller [9], Jeremy Shefner [10], Jean Paul Vonsattel [11], and Hiroshi Mitsumoto [12] [1] Neurological Clinical Research Institute (NCRI), Massachusetts General Hospital [2] National Institute of Neurological Disorders and Stroke (NINDS), NIH [3] Department of Clinical Neuroscience, Kings College London, Institute of Psychiatry [4] Division of Neurology, School of Medicine, Duke Institute for Brain Sciences [5] Department of Neurology, Massachusetts General Hospital [6] Department of Neurology, Georgetown University Medical Center [7] Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services [8] Prize4Life, Cambridge [9] The Forbes Norris MDA/ALS Research Center, California Pacific Medical Center [10] Department of Neuroscience and Physiology, SUNY Upstate Medical University [11] Department of Pathology and Cell Biology, New York-Presbyterian Hospital, Columbia University Medical Center [12] Eleanor and Lou Gehrig MDA/ALS Research Center, Department of Neurology, Columbia University Medical Center
Journal	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Summary	This publication focuses on the availability of infrastructure resources collecting clinical and patient oriented data that could bolster our understanding of the etiology and pathogenesis of ALS. The authors’ key recommendations were to 1) establish shared knowledge amongst ALS databases; 2) expand human biospecimen banks; 3) and adopt universal standards for ALS clinical research. Existing infrastructure resources for ALS clinical research include: the Western ALS Consortium, Northeast ALS Consortium, Prize4Life, University banks and repositories, ALS Research Group (ALSRG), ALS Clinical Research Leaning Institute, the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), and the National ALS Registry.
Link to paper	Find the paper hereexternal icon!

Page last reviewed: October 21, 2021

Content source: Agency for Toxic Substances and Disease Registry